Therefore, this finding suggests that BCR::ABL1-targeting TKI treatment could potentially downregulate the neddylation status of CML cells, thereby leading to the therapeutic insensitivity in a portion of patients. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.